Lindus Health Secures $55M to Revolutionize Clinical Trials

In a bold move to revolutionize the stagnant clinical trial industry, Lindus Health has secured $55 million in Series B funding led by Balderton Capital, with contributions from Visionaries Club, Creandum, Firstminute, and Seedcamp. Lindus Health positions itself as the 'anti-CRO,' challenging traditional contract research organizations with its innovative AI and tech-driven approach that speeds up trials threefold while maintaining superior data quality. The funding will be pivotal in expanding Lindus Health's AI technology and eClinical platform, Citrus, to further optimize study design and automate monitoring, enabling more efficient drug development processes. Launched in 2021, Lindus Health has already conducted numerous trials across various medical fields, demonstrating significant enhancement over existing methods. These advancements come in response to the clinical trial industry's historic issues of delays and inflated costs. The new funding is poised to propel Lindus Health into new heights as it seeks to fundamentally alter how clinical trials operate, unlocking faster and more cost-effective healthcare solutions for patients worldwide.